Three-gene test can identify which prostate cancers require treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow growing, according to new research. This three-gene biomarker, combined with existing cancer-staging tests, could help physicians better determine which men with early prostate cancer can be safely followed with “active surveillance” and spared the risks of prostate removal or other invasive treatment.
"Most of the 200,000 prostate cancers diagnosed each year in the US are slow growing and will remain so, but the three-gene biomarker could take much of the guesswork out of the diagnostic process and ensure that patients are neither overtreated nor undertreated," said study co–senior author Cory Abate-Shen, PhD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC) in New York, New York. The study was published in Science Translational Medicine (2013; doi: 10.1126/scitranslmed.3006408).
"The problem with existing tests is that we cannot identify the small percentage of slow-growing tumors that will eventually become aggressive and spread beyond the prostate," said coauthor Mitchell C. Benson, MD, PhD, also of CUMC.
In their search for a biomarker for slow-growing prostate cancer, Abate-Shen and her colleagues focused on genes related to aging, particularly those affected by cellular senescence. Cellular senescence is a natural phenomenon in which older cells cease to divide but remain metabolically active. Cellular senescence is known to play a critical role in tumor suppression in general and has been associated with benign prostate lesions in mouse models and in humans.
Using a technique called gene set enrichment analysis, the CUMC team identified 19 genes that are enriched in a mouse model of prostate cancer in which the cancers are invariably indolent. They then used a decision-tree learning model, which is a type of computer algorithm, to identify three genes—FGFR1, PMP22, and CDKN1A—that together can accurately predict the outcome of seemingly low-risk tumors. Tumors that test negative for the biomarker are deemed aggressive.
In a blinded retrospective study, the researchers tested the prognostic accuracy of the three-gene panel on initial biopsy specimens from 43 patients who had been monitored for at least 10 years with active surveillance at CUMC. All the patients had first been diagnosed with low-risk prostate cancer (as defined by several measures, including a Gleason score of 6 or less). Of the 43 patients, 14 ultimately developed advanced prostate cancer. All 14 were correctly identified by the test.
"The bottom line is that, at least in our preliminary trial, we were able to accurately predict which patients with low-risk prostate cancer would develop advanced prostate cancer and which ones would not," said Abate-Shen. A larger, prospective clinical trial is planned to further evaluate the biomarker.